How many gonorrhea cases will be reported in the United States in 2026?
$0.00
1
9
How many gonorrhea cases will be reported in the United States in 2026?
$0.00
1
9
AI Analysis
Trader mode: Actionable analysis for identifying opportunities and edge
About This Event
2026 If the total number of gonorrhea cases reported in the United States during 2026 is above X then the market resolves to Yes. Cases are determined at 10:00 AM ET on the Expiration Date, January 8. Cases that actually occur between the end of the specified time period and Expiration do not count, but newly reported cases during this window do count if they are backdated to 2026. See the full rules for how Source Agencies are prioritized. This market refers exclusively to human cases. This ma
Current Market Outlook
Kalshi traders are pricing a 94% probability that the United States will report more than 285,000 gonorrhea cases in 2026. That is a near-certain bet according to the market. For context, the CDC reported 648,056 gonorrhea cases in 2021, 648,056 in 2022, and roughly 600,000 in 2023. The threshold of 285,000 is less than half the recent annual totals. The market is effectively betting that gonorrhea transmission will not collapse by 55% or more in two years.
Key Factors Driving the Odds
The CDC's 2023 STD Surveillance Report showed gonorrhea rates declining 7.7% from 2022 to 2023, the first drop in a decade. But that still left 600,000 cases. Even if the decline accelerates to 15% per year through 2026, cases would land around 440,000, well above 285,000.
Two structural factors support the high probability. First, gonorrhea is often asymptomatic, especially in women, meaning reported cases always lag true infections. Second, the CDC's reporting system includes a multi-year lag for final counts, but initial reports from state health departments typically show only modest year-over-year swings. A 50% drop in two years would require a public health intervention on the scale of widespread vaccine distribution or a dramatic behavioral shift. Neither exists. Doxycycline post-exposure prophylaxis (doxy-PEP) is gaining traction but remains limited to specific high-risk populations in a few cities.
What Could Change These Odds
The most obvious path to a "No" resolution is a massive federal funding cut to STD surveillance programs. If reporting infrastructure collapses, case counts would drop artificially. But that is a bureaucratic failure, not a disease reduction. The market does not distinguish between fewer infections and fewer reports.
A second scenario: a new antibiotic-resistant strain emerges that changes testing or treatment protocols, causing temporary reporting disruptions. But even that would need to suppress counts below 285,000, which requires near-total cessation of testing.
The real risk to the 94% price is a correction if traders realize the threshold is too low. The market opened at 80% and climbed to 94% as volume increased. If new traders examine the data and see 600,000 cases as the baseline, they may push the price to 97% or 98%. But there is no arbitrage here. The bet is simply whether gonorrhea disappears in two years. It will not.
AI-generated analysis based on market data. Not financial advice.
Overview
Gonorrhea is a sexually transmitted infection (STI) caused by the bacterium Neisseria gonorrhoeae. In the United States, it is the second most commonly reported notifiable disease, after chlamydia. The Centers for Disease Control and Prevention (CDC) tracks gonorrhea cases through its National Notifiable Diseases Surveillance System (NNDSS), which collects reports from state and local health departments. The prediction market question asks how many gonorrhea cases will be reported in the U.S. in 2026, with a specific threshold that determines whether the market resolves to Yes or No. The resolution date is January 8, 2027, at 10:00 AM ET, allowing for a short window to catch late-reported cases backdated to 2026. This question is of interest because gonorrhea rates have fluctuated significantly in recent years, driven by factors like changes in screening practices, antibiotic resistance, and public health funding. The CDC reported about 648,000 cases in 2021, down from a peak of over 700,000 in 2019, but the trend is uncertain due to the COVID-19 pandemic's disruption of STI surveillance and healthcare access. The outcome of this market could reflect broader trends in sexual health, public health policy effectiveness, and the impact of new prevention tools like the antibiotic doxycycline post-exposure prophylaxis (doxy-PEP).
Historical Context
Gonorrhea has been a notifiable disease in the United States since the 1940s, with the CDC maintaining consistent surveillance data. Cases peaked in the 1970s at over 1 million per year, then declined through the 1980s and 1990s due to public health campaigns and the HIV epidemic's behavioral changes. The lowest point was in 2009, with about 301,000 cases. From 2010 to 2019, cases rose sharply, more than doubling to 616,000 in 2019. This increase was driven by factors like reduced condom use, improved screening, and social changes. The COVID-19 pandemic caused a drop in reported cases in 2020, to about 584,000, but this was partly due to reduced testing and healthcare access. Cases rebounded to 648,000 in 2021 and 648,000 again in 2022, suggesting the underlying trend is stable or slightly rising. The CDC's 2023 preliminary data showed about 600,000 cases, but final numbers are pending. The long-term trend is concerning because of rising antibiotic resistance. The CDC's GISP has found decreasing susceptibility to azithromycin and ceftriaxone, the current recommended dual therapy. In 2020, the first case of gonorrhea with high-level resistance to ceftriaxone was reported in the U.S., raising fears of untreatable infections.
Why It Matters
The number of gonorrhea cases reported in 2026 will reflect the state of STI prevention and public health infrastructure in the U.S. A high case count could indicate failures in screening, treatment, and education, leading to more complications like pelvic inflammatory disease, infertility, and ectopic pregnancy. It also increases the risk of antibiotic resistance spreading, which could make gonorrhea much harder and more expensive to treat. The economic burden is substantial: the CDC estimates that gonorrhea and its complications cost the U.S. healthcare system over $1 billion annually. For individuals, an infection can cause stigma, anxiety, and long-term health problems. Beyond health, the case count is a political issue. Federal funding for STI prevention has been flat for years, and some states have cut their own programs. The 2026 number could be used by advocates to push for more resources or by critics to argue that current approaches are not working. It also matters for global health, as the U.S. is a major source of data on resistance patterns, and high case numbers here can accelerate the spread of resistant strains worldwide. Researchers and public health officials will watch the 2026 count closely to gauge the impact of new interventions like doxy-PEP, which was recommended by the CDC in 2024 for certain high-risk groups.
Current Status
As of early 2025, the CDC has not yet released final gonorrhea case counts for 2023 or 2024. Preliminary data for 2023 suggested around 600,000 cases, but this is subject to revision. The 2024 count is being collected and analyzed. Key developments include the CDC's October 2024 recommendation of doxy-PEP for men who have sex with men (MSM) and transgender women with a recent STI, which could reduce gonorrhea incidence in high-risk groups. However, uptake is still low. Antibiotic resistance remains a concern, with ongoing surveillance through GISP. The COVID-19 pandemic's long-term effects on STI testing and healthcare access are still being felt, with some clinics reporting staffing shortages and reduced hours. The 2026 count will be influenced by these factors, as well as by any new public health campaigns, funding changes, or shifts in sexual behavior. The prediction market's threshold will determine whether the count is considered high or low relative to current expectations.
Frequently Asked Questions
How does the CDC count gonorrhea cases?
The CDC relies on mandatory reporting from healthcare providers and laboratories to state and local health departments, which then report to the NNDSS. Cases are defined by laboratory confirmation of Neisseria gonorrhoeae infection. The count includes only cases reported to the CDC, so it underestimates the true number of infections.
Why did gonorrhea cases drop in 2020?
The drop was primarily due to reduced STI testing and healthcare access during the COVID-19 pandemic, not a true decrease in infections. Many clinics closed or reduced hours, and people avoided seeking care. Cases rebounded in 2021 as services resumed.
What is doxy-PEP and how might it affect gonorrhea rates?
Doxy-PEP is the use of the antibiotic doxycycline taken within 72 hours after condomless sex to prevent STIs. The CDC recommended it in October 2024 for gay, bisexual, and other men who have sex with men and transgender women who have had a bacterial STI in the past year. Studies show it reduces gonorrhea risk by about 50% in this group, but it is not yet widely used.
Educational content is AI-generated and sourced from Wikipedia. It should not be considered financial advice.
